跳至主要内容
临床试验/NCT02410083
NCT02410083已完成4 期

Multicenter, Randomized, Open Study, Investigator-initiated Trial for Comparison of Eight Weeks Efficacy and Tolerability of Clopirin and Clopidogrel With Aspirin in Korean Patients With Post-Percutaneous Coronary Artery Intervention

Jeil Pharmaceutical Co., Ltd.0 个研究点目标入组 448 人开始时间: 2012年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
448
主要终点
% inhibition =△Purinergic receptor, G-protein coupled, 12 Reaction Units(PRU)/ Pretreatment PRU

研究概览

简要总结

The purpose of this study in to evaluate efficacy and tolerability of Clopirin and clopidogrel with aspirin in Korean Patients with post-percutaneous coronary artery intervention.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Over 3 months, the patient who were the administration of aspirin or the co-administration of clopidogrel-aspirin coronary artery patients after treated with Percutaneous Coronary Intervention(PCI) that have safety progress.
  • Korean men and women between the age of 20 and 85
  • Patients who understand the study requirements, are willing to comply with all study procedures and have provided written informed consent.

排除标准

  • Patients who were not treated with PCI or intended to treat with PCI but failed.
  • Patients who were taking or had taken other antiplatelet or anticoagulant for more than 2 weeks within the prior 30 days.
  • Patients who had a history of alcohol abuse or intoxication.
  • Patients who had hypersensitivity to clopidogrel or aspirin.
  • Patients who had severe hepatic dysfunction aspartate aminotransferase(AST) or alanine aminotransferase(ALT) > 3 times upper normal reference values.
  • Patients who had blood coagulation disorders, uncontrolled severe hypertension, active bleeding, or history of severe bleeding, such as intracranial hemorrhage or ulcer bleeding - surgery within 48hr, platelet counts below 50,000/mm3 in laboratory tests.
  • Patients who were pregnant, breastfeeding.
  • Patients who were not using effective methods of contraception. (proper contraception : hormonal contraception, condom, intrauterine device, spermicide)
  • Patients who medically, psychologically had investigational product administration's prohibition.
  • Patients who were not participated in this clinical trial decided by other investigators.

研究组 & 干预措施

Clopirin 1

Experimental

Clopirin single-administration. Before this clinical trial Clopidogrel/Aspirin co-administration.

干预措施: Clopirin 1 (Drug)

Clopidogrel/Aspirin co-administration 1

Active Comparator

Clopidogrel-aspirin co-administration. Before this clinical trialClopidogrel/Aspirin co-administration.

干预措施: Clopidogrel-Aspirin(co-administration) 1 (Drug)

Clopirin 2

Experimental

Clopirin single-administration. Before this clinical trial Aspirin single-administration.

干预措施: Clopirin 2 (Drug)

Clopidogrel/Aspirin co-administration 2

Active Comparator

Clopidogrel-aspirin-co-administration. Before this clinical trial Aspirin single-administration.

干预措施: Clopidogrel-Aspirin(co-administration) 2 (Drug)

结局指标

主要结局

% inhibition =△Purinergic receptor, G-protein coupled, 12 Reaction Units(PRU)/ Pretreatment PRU

时间窗: 8 weeks

次要结局

  • △ PRU = Post treatment PRU - Pre treatment PRU(8 weeks)
  • △ ARU = Post treatment Aspirin resistance unit(ARU) - Pre treatment ARU(8 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Trial to Assess the Efficacy of Combination Formula... | 临床试验